HUTCHMED (China) Limited (H7T1) - Cash Flow Conversion Efficiency
Based on the latest financial reports, HUTCHMED (China) Limited (H7T1) has a cash flow conversion efficiency ratio of -0.140x as of December 2022. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-89.37 Million ≈ $-104.48 Million USD) by net assets (€636.87 Million ≈ $744.57 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See H7T1 net asset quality index to measure how much of total assets are equity-financed.
HUTCHMED (China) Limited - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how HUTCHMED (China) Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check H7T1 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
HUTCHMED (China) Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of HUTCHMED (China) Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mercuries Life Insurance Co Ltd
TW:2867
|
-0.072x |
|
Visual China Group Co Ltd
SHE:000681
|
0.012x |
|
Wisdom Marine Lines Co Ltd
TW:2637
|
0.055x |
|
Wedge Industrial Co Ltd
SHE:000534
|
0.006x |
|
Iluka Resources Ltd
AU:ILU
|
-0.039x |
|
China TransInfo Technology Co Ltd
SHE:002373
|
0.022x |
|
RLX Technology Inc
NYSE:RLX
|
0.022x |
|
Burkhalter Holding AG
SW:BRKN
|
0.638x |
Annual Cash Flow Conversion Efficiency for HUTCHMED (China) Limited (2016–2025)
The table below shows the annual cash flow conversion efficiency of HUTCHMED (China) Limited from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see HUTCHMED (China) Limited market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €1.25 Billion ≈ $1.46 Billion |
€-64.66 Million ≈ $-75.59 Million |
-0.052x | -8125.01% |
| 2024-12-31 | €771.85 Million ≈ $902.38 Million |
€497.00K ≈ $581.05K |
0.001x | -99.78% |
| 2023-12-31 | €743.39 Million ≈ $869.10 Million |
€219.26 Million ≈ $256.34 Million |
0.295x | +169.93% |
| 2022-12-31 | €636.87 Million ≈ $744.57 Million |
€-268.60 Million ≈ $-314.02 Million |
-0.422x | -114.67% |
| 2021-12-31 | €1.04 Billion ≈ $1.22 Billion |
€-204.22 Million ≈ $-238.76 Million |
-0.196x | -64.27% |
| 2020-12-31 | €518.95 Million ≈ $606.71 Million |
€-62.07 Million ≈ $-72.56 Million |
-0.120x | +53.75% |
| 2019-12-31 | €312.90 Million ≈ $365.82 Million |
€-80.91 Million ≈ $-94.59 Million |
-0.259x | -224.54% |
| 2018-12-31 | €412.25 Million ≈ $481.97 Million |
€-32.85 Million ≈ $-38.40 Million |
-0.080x | -332.07% |
| 2017-12-31 | €484.97 Million ≈ $566.98 Million |
€-8.94 Million ≈ $-10.46 Million |
-0.018x | +60.68% |
| 2016-12-31 | €204.06 Million ≈ $238.57 Million |
€-9.57 Million ≈ $-11.19 Million |
-0.047x | -- |
About HUTCHMED (China) Limited
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast c… Read more